Previous Posts
- Botulinum Toxin Drugs Get New Black Box Warning
- Certain Popular Nutritional Supplements May be Dan...
- FDA Approves New Type 2 Diabetes Drug
- Teva Animal Health Inc. is Banned from Distributin...
- EPA Issues New Administrative Order for Doe Run Cl...
- iPhone may be Vulnerable to Hacker Attacks
- Restrictive Diets may not be Appropriate for Child...
- U.S. Supreme Court Decision May Impact Drug, DUI C...
- Updated Safety Information for Colchicine
Click Here to View
Our Other Site
Wednesday, August 5, 2009
FDA Requires New Warning for TNF Blockers
The FDA announced yesterday that it had completed its review of tumor necrosis factor (TNF) blockers and that it had concluded that there is an increased risk of cancer in children and adolescents who use TNF blockers. The current prescribing information for TNF blockers does contain a warning for malignancies, but it does not specifically mention leukemia. TNF blockers are approved for the treatment of multiple immune system diseases including Crohn’s disease, rheumatoid arthritis, psoriatic arthirtis, plaque psoriasis, and juvenile idiopathic arthritis.
When a person suffers from chronic inflammatory diseases, such as the ones listed above, their body overproduces a protein called tumor necrosis factor-alpha (TNF-a). When this protein exists in large quantities in the body, it can cause inflammation and damage to bones, cartilage, and tissue. When patients suffering from chronic inflammatory diseases take TNF blockers, the drug targets the overproduced TNF-a and neutralizes it. Brand names of TNF blockers include Remicade (infliximab), Enbrel (etancercept), Humira (adalimumab), Cinzia (cetolizumab pegol), and Simponi (golimumab).
The law firm of Schlichter, Bogard & Denton is currently investigating claims against the manufacturers of Remicade, Enbrel, and Humira. If you or a loved one has suffered adverse events from the above mentioned drugs, please contact an experienced pharmaceutical attorney at Schlichter, Bogard & Denton. We serve clients nationwide.
For more information, see the FDA Press Announcement at:
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm175803.htm
See the MedWatch Safety Information at:
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm175843.htm
When a person suffers from chronic inflammatory diseases, such as the ones listed above, their body overproduces a protein called tumor necrosis factor-alpha (TNF-a). When this protein exists in large quantities in the body, it can cause inflammation and damage to bones, cartilage, and tissue. When patients suffering from chronic inflammatory diseases take TNF blockers, the drug targets the overproduced TNF-a and neutralizes it. Brand names of TNF blockers include Remicade (infliximab), Enbrel (etancercept), Humira (adalimumab), Cinzia (cetolizumab pegol), and Simponi (golimumab).
The law firm of Schlichter, Bogard & Denton is currently investigating claims against the manufacturers of Remicade, Enbrel, and Humira. If you or a loved one has suffered adverse events from the above mentioned drugs, please contact an experienced pharmaceutical attorney at Schlichter, Bogard & Denton. We serve clients nationwide.
For more information, see the FDA Press Announcement at:
http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm175803.htm
See the MedWatch Safety Information at:
http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm175843.htm
Labels: Crohn's disease, enbrel, humira, remicade, TNF Blockers, tnf-a
posted by
Colleen
at
8:07 AM
<< Home